Diabetes & Metabolism Journal

Reviews

Pathophysiology
Epicardial Adipose Tissue and Heart Failure, Friend or Foe?: Dong-Hyuk Cho, Seong-Mi Park; Diabetes Metab J. 2024;48(3):373-384. Published online February 2, 2024; DOI: https://doi.org/10.4093/dmj.2023.0190

11,917 View
485 Download
25 Web of Science
27 Crossref

Heart failure (HF) management guidelines recommend individualized assessments based on HF phenotypes. Adiposity is a known risk factor for HF. Recently, there has been an increased interest in organ-specific adiposity, specifically the role of the epicardial adipose tissue (EAT), in HF risk. EAT is easily assessable through various imaging modalities and is anatomically and functionally connected to the myocardium. In pathological conditions, EAT secretes inflammatory cytokines, releases excessive fatty acids, and increases mechanical load on the myocardium, resulting in myocardial remodeling. EAT plays a pathophysiological role in characterizing both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). In HFrEF, EAT volume is reduced, reflecting an impaired metabolic reservoir, whereas in HFpEF, the amount of EAT is associated with worse biomarker and hemodynamic profiles, indicating increased EAT activity. Studies have examined the possibility of therapeutically targeting EAT, and recent studies using sodium glucose cotransporter 2 inhibitors have shown potential in reducing EAT volume. However, further research is required to determine the clinical implications of reducing EAT activity in patients with HF.

Citations

Citations to this article as recorded by

Fine-grained epicardial adipose tissue segmentation in cardiac CT images with position priors and edge enhancement
Sheng Lian, Qinghe Yuan, Qiong Su, Jiayao Liu, Dajun Chai
Biomedical Engineering Letters.2026; 16(1): 11. CrossRef
Heart matters: How glucose‐ and lipid‐modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning
Elisabeth Heuboeck, Charnkamal Singh Bhogal, Markus Mandl
Diabetes, Obesity and Metabolism.2026; 28(2): 878. CrossRef
The Metabolic Heart: Reframing Heart Failure With Preserved Ejection Fraction as a Systemic Cardio-Metabolic Syndrome
Debasrita Baidya, Abhishek Hanumanpratap Singh Kshatri, Emi K Zerzan, Gayathri J Menon, Mihika Sawale, Sunny Subhash Bhalodiya
Cureus.2026;[Epub] CrossRef
Cardiometabolic Crossroads: Obesity, Sleep-Disordered Breathing, and Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction – A Mini-Review
Fulvio Cacciapuoti, Ciro Mauro, Valentina Capone, Angelo Sasso, Luca Gaetano Tarquinio, Federico Cacciapuoti
Heart and Mind.2025; 9(2): 147. CrossRef
Empagliflozin in diabetic cardiomyopathy: elucidating mechanisms, therapeutic potentials, and future directions
Aiswarya Jaiswal, Poonam Yadav, Pushkar Singh Rawat, Maninder Kaur, Srivalliputturu Sarath Babu, Amit Khurana, Jasvinder Singh Bhatti, Umashanker Navik
Molecular Biology Reports.2025;[Epub] CrossRef
Mediating Role of Blood Metabolites in the Relationship Between Immune Cell Traits and Heart Failure: A Mendelian Randomization and Mediation Analysis
Yi Liu, Chenfu Shen, Yu Cao
Journal of the American Heart Association.2025;[Epub] CrossRef
Sex Difference in the Association Between Regional Adipose Tissue and Left Ventricular Hypertrophy
In-Jeong Cho, Sang-Eun Lee, Wook-Bum Pyun
Journal of Clinical Medicine.2025; 14(7): 2399. CrossRef
Obesity and its management in primary care setting
Mahmoud Ibrahim, Ebtesam M. Ba-Essa, Jessica A. Alvarez, Jason Baker, Vincenzo Bruni, Avivit Cahn, Antonio Ceriello, Francesco Cosentino, Melanie J. Davies, Francesco De Domenico, Robert H. Eckel, Allon N. Friedman, Jonathan Goldney, Omer Hamtzany, Scott
Journal of Diabetes and its Complications.2025; 39(7): 109045. CrossRef
Differential Association of Regional Adipose Tissue Deposit with Cardiovascular-Kidney-Metabolic Syndrome
In-Jeong Cho, Sang-Eun Lee, Wook Bum Pyun
Cardiorenal Medicine.2025; 15(1): 285. CrossRef
Epicardial Adipose Tissue and Heterogeneity Parameters Combined with Inflammatory Cells to Predict the Value of Heart Failure with Preserved Ejection Fraction Patients Post Myocardial Infarction
Yu-jiao Song, Xiao-ying Zhao, Lu-jing Wang, Ting Ning, Ming-tian Chen, Pei Liu, Si-wen Chen, Xin-xiang Zhao
Cardiovascular Diabetology.2025;[Epub] CrossRef
THE RELATIONSHIP BETWEEN EPICARDIAL AND PARACARDIAL FAT THICKNESS AND DISEASE SEVERITY IN ELDERLY PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Gülhan AYHAN ALBAYRAK, Mustafa İlteriş BARDAKÇI, Goncagül BÜLBÜN
Turkish Journal of Geriatrics.2025;[Epub] CrossRef
Heart-guarding or heart-harming? The dual role of epicardial adipose tissue in cardiovascular health and disease
Yu Tian, Pingping Wang, Zhifeng Dong
International Journal of Obesity.2025; 49(11): 2156. CrossRef
Advances and challenges of targeting epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT)
Dan Liu, Wujun Chen, Zhu Guo, Qun Gao, Bin Wang, Jie Wang, Weichao Hu, Chao Wang, Shuai Wang, Xiaolin Wu, Mantao Xu, Ganqiu Lan
Cardiovascular Diabetology.2025;[Epub] CrossRef
Association of epicardial adipose tissue and biventricular strain in heart failure with preserved and reduced ejection fraction
Yu-jiao Song, Ting Ning, Ming-tian Chen, Xiao-ying Zhao, Wan-qiu Zhang, Lu-jing Wang, Xin-xiang Zhao
Journal of Cardiovascular Magnetic Resonance.2025; 27(2): 101935. CrossRef
Construction of a Novel Secreted Protein Database and Identification of a New Adipokine CRELD2
Shu-Na Wang, Zhi-Yong Li, Qi-Sheng Ling, Peng-Fei Jing, Wen-Yu Liu, Yi-Jie Zhang, Xiu-Ping Zhang, Xi-Yuan Wang, Fu-Qiang Chang, Zhu-Wei Miao, Jing-Xin Zhao, Jin Chen, Chao-Yu Miao
Diabetes & Metabolism Journal.2025; 49(5): 1006. CrossRef
Beyond Traditional Risk Factors: Integrating Epicardial Adipose Tissue into the Comorbidity Landscape of HFpEF
Marius-Dragoș Mihăilă, Bogdan Caloian, Florina Iulia Frîngu, Diana Andrada Irimie, Ioan Alexandru Minciună, Dana Pop
Journal of Clinical Medicine.2025; 14(17): 6139. CrossRef
Impact of epicardial adipose tissue volume and hypertension on left ventricular hypertrophy in preclinical heart failure patients with metabolic syndrome
Junshi Xie, Zhiqiang Liu, Anqi Cheng, Lei Gao
BMC Cardiovascular Disorders.2025;[Epub] CrossRef
Cardiac magnetic resonance quantification of epicardial adipose tissue identifies subclinical cardiac dysfunction in asymptomatic obesity: A multicenter cross‐sectional study
Xu Wang, Hang Zhao, Jiang Yue, Yezi Chai, Jing Ma, Meng Jiang, Jun Pu
VIEW.2025;[Epub] CrossRef
Advances in Molecular Mechanisms and Precision Interventions of Cardiovascular Injuries Related to Glucose and Lipid Metabolism Disorders
Li Wu, Jiyao Xu, Chenxia Wu, Minyan Wang, Tingting Chen, Conghua Ji, Wei Mao
Reviews in Cardiovascular Medicine.2025;[Epub] CrossRef
Epicardial adipose tissue: an overtly concealed contributor to cardiovascular events in chronic kidney disease patients
Liqin Cui, Min Yang
Lipids in Health and Disease.2025;[Epub] CrossRef
New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review
Jorge E. Jalil, Luigi Gabrielli, María Paz Ocaranza, Paul MacNab, Rodrigo Fernández, Bruno Grassi, Paulina Jofré, Hugo Verdejo, Monica Acevedo, Samuel Cordova, Luis Sanhueza, Douglas Greig
International Journal of Molecular Sciences.2024; 25(8): 4407. CrossRef
Association of body adiposity with left ventricular concentric remodeling and diastolic dysfunction
In‐Jeong Cho, Sang‐Eun Lee, Wook Bum Pyun
Echocardiography.2024;[Epub] CrossRef
Statin Therapy Mitigates Oxidative Stress in Epicardial and Perivascular Adipose Tissue: A Pilot Study in Cardiac Surgery Patients
Laurentiu Braescu
Timisoara Medical Journal.2024; 2024(1): 1. CrossRef
Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction
Tian-Yu Wang, Qiang Yang, Xin-Yi Cheng, Jun-Can Ding, Peng-Fei Hu
Heart Failure Reviews.2024; 30(1): 17. CrossRef
Predictive value of epicardial adipose tissue volume measured in diagnosis and prognosis of patients with HFPEF
Yunlu Jiang, Li Su
Experimental Gerontology.2024; 198: 112618. CrossRef
Huangqi-Danshen decoction improves heart failure by regulating pericardial adipose tissue derived extracellular vesicular miR-27a-3p to activate AMPKα2 mediated mitophagy
Zhaoyang Chen, Meng Zhang, Qiyao Xu, Pengyu Lu, Min Liu, Rui Yin, Xuan Liu, Yang Dai, Xin Gao, Juexiao Gong, Sujie Zhang, Xindong Wang
Phytomedicine.2024; 135: 156187. CrossRef
Targeting Cardiac Fibrosis in Diabetic Heart Failure: The Role of the EZH2, AMPK, and PPAR-γ Pathways (Diabetes Metab J 2024;48:716-29)
Jooyeop Lee, Joon Ho Moon
Diabetes & Metabolism Journal.2024; 48(6): 1176. CrossRef

Guideline/Fact Sheet
Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement: Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon, The Committee of Clinical Practice Guidelines, Korean Diabetes Association and Committee of Clinical Practice Guidelines, Korean Society of Heart Failure; Diabetes Metab J. 2023;47(1):10-26. Published online January 26, 2023; DOI: https://doi.org/10.4093/dmj.2022.0420

13,392 View
520 Download
12 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Diabetes mellitus is a major risk factor for the development of heart failure. Furthermore, the prognosis of heart failure is worse in patients with diabetes mellitus than in those without it. Therefore, early diagnosis and proper management of heart failure in patients with diabetes mellitus are important. This review discusses the current criteria for diagnosis and screening tools for heart failure and the currently recommended pharmacological therapies for heart failure. We also highlight the effects of anti-diabetic medications on heart failure.

Citations

Citations to this article as recorded by

Concurrent diabetes and heart failure: revisiting epidemiological and clinicopathological interplay
Jayagopal Pathiyil Balagopalan, Sandeep Bansal, Arpandev Bhattacharyya, Abdul Hamid Zargar, Sameer Dani, Abhijit Taraphder, Alan Almeida, Nilakshi Deka, Sanjay Jain, Onkar C. Swami
Diabetology International.2026;[Epub] CrossRef
The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation
Yongin Cho, Sung-Hee Shin, Min-Ae Park, Young Ju Suh, Sojeong Park, Ji-Hun Jang, Dae-Young Kim, So Hun Kim, Xinlin Zhang
PLOS ONE.2025; 20(2): e0314454. CrossRef
A Multicenter, Randomized, Open‐Label Study to Compare the Effects of Gemigliptin Add‐on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT‐2 Inh
Hae Jin Kim, Jung Hyun Noh, Min Kyong Moon, Sung Hee Choi, Seung-Hyun Ko, Eun-Jung Rhee, Kyu Yeon Hur, In-Kyung Jeong, Mark Yorek
Journal of Diabetes Research.2024;[Epub] CrossRef
Epicardial Adipose Tissue and Heart Failure, Friend or Foe?
Dong-Hyuk Cho, Seong-Mi Park
Diabetes & Metabolism Journal.2024; 48(3): 373. CrossRef
Adiposity modifies the association between heart failure risk and glucose metabolic disorder in older individuals: a community-based prospective cohort study
Liming Hou, Xin Wang, Peilin Li, Hua Zhang, Yanli Yao, Zhendong Liu, Juan Wang, Weike Liu
Cardiovascular Diabetology.2024;[Epub] CrossRef
Paper-based colorimetric microfluidic device for visual detection of glucose coupling different-shaped gold nanostructures with cerium oxide nanozyme
Fareeha Arshad, Koo Pey Ting, Siti Nurul Azian Zakaria, Noor Faizah Mohd-Naim, Ying Woan Soon, Minhaz Uddin Ahmed
Applied Materials Today.2024; 41: 102451. CrossRef
Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study
Seung Min Chung, Jun Sung Moon, Jun Hwa Hong, In‐Chang Hwang, Soo Lim
Diabetes, Obesity and Metabolism.2023; 25(8): 2181. CrossRef
Optimization of guideline-directed medical treatment for heart failure patients with reduced ejection fraction
Minjung Bak, Jin-Oh Choi
The Korean Journal of Internal Medicine.2023; 38(5): 595. CrossRef

Original Article

Metabolic Risk/Epidemiology
Longitudinal Change in Myocardial Function and Clinical Parameters in Middle-Aged Subjects: A 3-Year Follow-up Study: Dong-Hyuk Cho, Hyung Joon Joo, Mi-Na Kim, Hee-Dong Kim, Do-Sun Lim, Seong-Mi Park; Diabetes Metab J. 2021;45(5):719-729. Published online June 15, 2021; DOI: https://doi.org/10.4093/dmj.2020.0132

7,635 View
129 Download
3 Web of Science
3 Crossref

Graphical Abstract Abstract PDF PubReader ePub

Background
Metabolic syndrome (MetS) is closely associated with the aging process. However, changes in metabolic conditions and cardiac function that occur in middle aged population remain unclear. We evaluated longitudinal changes in metabolic parameters and cardiac function during a 3-year period in subjects with suspected MetS.
Methods
We studied 191 participants with suspected MetS at baseline and after 3 years. Anthropometric parameters, including waist circumference (WC), and metabolic parameters, including fasting blood glucose and lipid profile were measured. Conventional echocardiography with two-dimensional speckle tracking was performed.
Results
Mean age was 56.2±4.4 years, and there were 97 women (50.8%). Men had increased WC and triglycerides (TG) (WC 91.2±6.8 cm vs. 84.0±8.0 cm, P<0.001; TG 184.4±116.3 mg/dL vs. 128.2±53.6 mg/dL, P<0.001), and reduced global longitudinal strain (GLS) (–15.4%±2.1% vs. –17.1%±2.0%, P<0.001) compared to women. After 3.4 years, values of WC and TG did not change in men but increased in women (all P<0.05). The absolute value of left ventricular (LV) GLS did not change in men but was reduced in women (P=0.011). Change in TG was independently associated with worsening of LV GLS only in women (standardized β, –0.309; 95% confidence interval, –0.130 to –0.009; P=0.025).
Conclusion
In middle aged population, a vulnerable period for metabolic disturbance, cardiac remodeling tended to progress, which was prominent in women. Progression of adiposity and dyslipidemia after menopause may accelerate subclinical cardiac remodeling in middle-aged women. Lifestyle modification and medical interventions may help prevent further cardiac dysfunction in these subjects.

Citations

Citations to this article as recorded by

Positive additive interaction effects of age, sex, obesity, and metabolic syndrome on left ventricular dysfunction
Dan Zhou, Zhongwen Ye, Zhiqiang Nie, Chaolei Chen, Songyuan Luo, Mengqi Yan, Jiabin Wang, Yingqing Feng
Journal of Diabetes.2024;[Epub] CrossRef
Epicardial Adipose Tissue and Heart Failure, Friend or Foe?
Dong-Hyuk Cho, Seong-Mi Park
Diabetes & Metabolism Journal.2024; 48(3): 373. CrossRef
Lung-Heart Outcomes and Mortality through the 2020 COVID-19 Pandemic in a Prospective Cohort of Breast Cancer Radiotherapy Patients
Vincent Vinh-Hung, Olena Gorobets, Nele Adriaenssens, Hilde Van Parijs, Guy Storme, Dirk Verellen, Nam P. Nguyen, Nicolas Magne, Mark De Ridder
Cancers.2022; 14(24): 6241. CrossRef

First
Prev
Page of 1
Next
Last

Search